Pentraxin‐3 modulates lipopolysaccharide‐induced inflammatory response and attenuates liver injury

Luis Perea, Mar Coll, Lucia Sanjurjo, Delia Blaya, Adil El Taghdouini, Daniel Rodrigo‐Torres, José Altamirano, Isabel Graupera, Beatriz Aguilar‐Bravo, Marta Llopis, Julia Vallverdú, Joan Caballeria, Leo A. van Grunsven, Maria‐Rosa Sarrias, Pere Ginès, Pau Sancho‐Bru – 19 April 2017 – Acute‐on‐chronic liver injury is characterized by an important inflammatory response frequently associated with endotoxemia. In this context, acute‐phase proteins such as Pentraxin‐3 (PTX3) are released; however, little is known about their role in chronic liver disease.

Development of a novel frailty index to predict mortality in patients with end‐stage liver disease

Jennifer C. Lai, Kenneth E. Covinsky, Jennifer L. Dodge, W. John Boscardin, Dorry L. Segev, John P. Roberts, Sandy Feng – 19 April 2017 – Cirrhosis is characterized by muscle wasting, malnutrition, and functional decline that confer excess mortality not well quantified by the Model for End‐Stage Liver Disease (MELD) Sodium (MELDNa) score. We aimed to develop a frailty index to capture these extrahepatic complications of cirrhosis and enhance mortality prediction in patients with cirrhosis.

Up‐regulation of golgi α‐mannosidase IA and down‐regulation of golgi α‐mannosidase IC activates unfolded protein response during hepatocarcinogenesis

Hsiao‐Chen Tu, Yung‐Chun Hsiao, Wan‐Yu Yang, Shin‐Lin Tsai, Hua‐Kuo Lin, Chong‐Yi Liao, Jeng‐Wei Lu, Yu‐Ting Chou, Horng‐Dar Wang, Chiou‐Hwa Yuh – 19 April 2017 – α‐1,2 mannosidases, key enzymes in N‐glycosylation, are required for the formation of mature glycoproteins in eukaryotes. Aberrant regulation of α‐1,2 mannosidases can result in cancer, although the underlying mechanisms are unclear. Here, we report the distinct roles of α‐1,2 mannosidase subtypes (MAN1A, MAN1B, ERMAN1, MAN1C) in the formation of hepatocellular carcinoma (HCC).

Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C–positive recipients

Silvia Martini, Francesco Tandoi, Lodovico Terzi di Bergamo, Silvia Strona, Bruna Lavezzo, Marco Sacco, Francesca Maione, Federica Gonella, Paolo Strignano, Dominic Dell Olio, Mauro Salizzoni, Giorgio Maria Saracco, Renato Romagnoli – 19 April 2017 – Although early allograft dysfunction (EAD) negatively impacts survival from the first months following liver transplantation (LT), direct‐acting antiviral agents (DAAs) have revolutionized hepatitis C virus (HCV) therapy.

Subscribe to